Biofrontera AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
September 03, 2018 at 11:05 am EDT
Share
DGAP Voting Rights Announcement: Biofrontera AG
Biofrontera AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
03.09.2018 / 17:00
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Notification of Major Holdings
1. Details of issuer
Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
2. Reason for notification
X
Acquisition/disposal of shares with voting rights
Acquisition/disposal of instruments
Change of breakdown of voting rights
Other reason:
3. Details of person subject to the notification obligation
Name:
City and country of registered office:
Mr Wilhelm K. T. Zours, Date of birth: 28 Jul 1961
4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
DELPHI Unternehmensberatung Aktiengesellschaft, Deutsche Balaton Aktiengesellschaft
5. Date on which threshold was crossed or reached:
29 Aug 2018
6. Total positions
% of voting rights attached to shares (total of 7.a.)
% of voting rights through instruments (total of 7.b.1 + 7.b.2)
total of both in % (7.a. + 7.b.)
total number of voting rights of issuer
Resulting situation
20.06 %
3.74 %
20.06 %
44541980
Previous notification
15.04 %
3.75 %
15.04 %
/
7. Notified details of the resulting situation a. Voting rights attached to shares (Sec.s 33, 34 WpHG)
ISIN
absolute
in %
direct (Sec. 33 WpHG)
indirect (Sec. 34 WpHG)
direct (Sec. 33 WpHG)
indirect (Sec. 34 WpHG)
DE0006046113
8,935,384
%
20.06 %
Total
8,935,384
20.06 %
b.1. Instruments according to Sec. 38 para. 1 No. 1 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Voting rights absolute
Voting rights in %
%
Total
%
b.2. Instruments according to Sec. 38 para. 1 No. 2 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Cash or physical settlement
Voting rights absolute
Voting rights in %
Convertible bond
15.07.2018 - 09.12.2019
discretionary of the bond issuer
1,667,000
3.74 %
Total
1,667,000
3.74 %
8. Information in relation to the person subject to the notification obligation
Person subject to the notification obligation is not controlled and does itself not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer (1.).
X
Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:
Name
% of voting rights (if at least held 3% or more)
% of voting rights through instruments (if at least held 5% or more)
Total of both (if at least held 5% or more)
Wilhelm K.T. Zours
%
%
%
DELPHI Unternehmensberatung Aktiengesellschaft
7.48 %
%
7.48 %
VV Beteiligungen Aktiengesellschaft
%
%
%
Deutsche Balaton Aktiengesellschaft
9.67 %
%
9.67 %
ABC Beteiligungen AG
%
%
%
Wilhelm K.T. Zours
%
%
%
DELPHI Unternehmensberatung Aktiengesellschaft
7.48 %
%
7.48 %
VV Beteiligungen Aktiengesellschaft
%
%
%
Deutsche Balaton Aktiengesellschaft
9.67 %
%
9.67 %
Deutsche Balaton Biotech AG
%
%
%
Wilhelm K.T. Zours
%
%
%
DELPHI Unternehmensberatung Aktiengesellschaft
7.48 %
%
7.48 %
VV Beteiligungen Aktiengesellschaft
%
%
%
Deutsche Balaton Aktiengesellschaft
9.67 %
%
9.67 %
Prisma Equity AG
%
%
%
9. In case of proxy voting according to Sec. 34 para. 3 WpHG
Date of general meeting:
Holding position after general meeting:
% (equals voting rights)
10. Other explanatory remarks:
There is no aggregation of voting rights related to the financial instrument referred to under 7.b.2, since this financial instrument has been issued by DELPHI Unternehmensberatung Aktiengesellschaft and these voting rights are already accounted for.
03.09.2018 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
Biofrontera AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution